Aspenwood Counseling And Behavior Center | |
225 South Street Albion ID 83311-0111 | |
(208) 312-2510 | |
Not Available |
Full Name | Aspenwood Counseling And Behavior Center |
---|---|
Speciality | Clinic/center - Adolescent And Children Mental Health |
Location | 225 South Street, Albion, Idaho |
Authorized Official Name and Position | Janet Ruth Loveland (COUNSELOR) |
Authorized Official Contact | 2083122510 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Aspenwood Counseling And Behavior Center Box 111 Albion ID 83311 Ph: (208) 312-2510 | Aspenwood Counseling And Behavior Center 225 South Street Albion ID 83311-0111 Ph: (208) 312-2510 |
NPI Number | 1518217983 |
---|---|
Provider Enumeration Date | 09/13/2012 |
Last Update Date | 09/13/2012 |
Identifier | Type | State | Issuer |
---|---|---|---|
1518217983 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
261QM0850X | Clinic/center - Adult Mental Health | 3745 (Idaho) | Secondary |
261QM0855X | Clinic/center - Adolescent And Children Mental Health | 3745 (Idaho) | Primary |
News Archive
Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.
Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.
According to an Access Economics study commissioned by the Alzheimer's Australia the number of Victorian dementia patients will quadruple in the next 40 years. At present the figures stand at 66,000 and are expected to touch 246,000 in 2050. The rise is an alarming 275% and is fueled by population growth, reduced physical activity, and an increasingly ageing population. Alzheimer's Australia warns Victorian Health authorities to start planning for measures to curb the epidemic.
The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.
Several diseases occur when mutations cause misfolding of proteins. These include "serpinopathies" which is a group of rare heritable diseases. They are caused by mutations of so-called "serpin" inhibitors of proteolytic enzymes involved in blood coagulation, tissue remodeling, and other important physiological functions.
› Verified 1 days ago